研究员，博导，国家海外高层次人才。现任四川大学华西医院肝肠疾病与代谢研究室主任。致力于肝损伤的代谢调控与干预药物研究，获准国家重点研发计划、国自然等项目10余项。在Nature Communications等SCI杂志上发表SCI论文110余篇，论文总引用次数超过4800次，单篇论文最高被引用700多次，H影响指数33，入选“美国斯坦福大学全球前2%顶尖科学家榜单”。获准专利5项，荣获中国药学会-赛诺菲青年生物药物奖、中国商业联合会科学技术奖二等奖。
1. 中国药理学会药物代谢专业委员会青年委员会委员；
2. 中国药理学会分析药理学专业委员会青年委员会委员；
3. 中华中医药学会青年委员会常务委员。
1、主要研究课题
1. 国家重点研发计划项目，20225/01-2025/12，在研，子课题负责人；
2. 国家重点研发计划项目：2018/01-2012/12，结题，子课题负责人；
3. 国家药品食品监督管理局项目，2020/01-2021/12，结题，子课题负责人。
2、代表论著
1. Q. Zhao, M. Dai, R. Huang, J. Duan, T. Zhang, W. Bao, J. Zhang, S. Gui, S. Xia, C. Dai, Y. Tang*, F. J. Gonzalez, F. Li*. Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice. Nature Communications 14(1): 1829 (2023).
2. R. Huang, C. Wang, Z.E. Wu, Q. Zhao, J. Duan, W. Huang, Y. Cheng, B. Zhu*, F. Li*. Metabolomics reveals that sulfotransferase 1 may regulate colchicine-induced liver injury. Chemico-Biological Interactions 386: 110776 (2023)
3. M. Dai, W. Peng, L. Lin, Z.E. Wu, T. Zhang, Q. Zhao, Y. Cheng, Q. Lin, B. Zhang, A. Liu b, Q. Rao, J. Huang, J. Zhao*, F.J. Gonzalez, F. Li*. Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii. Phytomedicine 121: 155054 (2023)
4. Q. Zhao#, Z. Wu#, B. Li, F. Li*. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacology & Therapeutics 237: 108256 (2022)
5. J. Huang, Q. Zhao, M. Dai, X. Xiao, T. Zhang, W. Zhu, F. Li*. Gut microbiota protects from triptolide-induced hepatotoxicity: Key role of propionate and its downstream signalling events. Pharmacological Research 155: 104752 (2020).
6. Q. Zhao#, J. Huang#, Y. Cheng, M. Dai, W. Zhu*, X. Yang, F.J. Gonzalez, F. Li*. Polyamine metabolism links gut microbiota and testicular dysfunction. Microbiome 9:224 (2021).
7. Z. Zhou, Y. Wang, D. Yan, J. Fang, X. Xiao, T. Zhang, Y. Cheng, K. Xu, F. Li*. Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics. Journal of Pharmaceutical and Biomedical Analysis 180: 113045 (2019).
8. Q. Zhao, T. Zhang, X. Xiao, J. Huang, Y. Wang, F.J. Gonzalez, F. Li*. Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity. British Journal of Pharmacology 176: 2162-2178 (2019).
9. X. Yang#, Y. Wang#, X. Zhu, X. Xiao, M. Dai, T. Zhang, Y. Qu, X. Yang, H. Qin, F. J. Gonzalez, F. Li*. Metabolic activation of elemicin leads to the inhibition of stearoyl-CoA desaturase 1. Chemical Research in Toxicology 32: 1965-1967 (2019).
研究生部公众号